linkstream2 microblog

http://bits.blogs.nytimes.com/2015/04/24/apple-watch-has-landed-heres-what-you-need-to-know/?smid=tw-nytimes&_r=1

http://www.nytimes.com/2015/04/24/technology/amazon-reports-big-profits-in-its-cloud-computing-business.html?smprod=nytcore-iphone&smid=nytcore-iphone-share&_r=0

http://www.ncbi.nlm.nih.gov/pubmed/25477383

also
http://www.ncbi.nlm.nih.gov/pubmed/25477383
Nucleic Acids Res. 2015 Feb 27;43(4):e23. doi: 10.1093/nar/gku1252. Epub 2014 Dec 3.
Allele-specific copy number profiling by next-generation DNA sequencing. Chen H1, Bell JM2, Zavala NA2, Ji HP2, Zhang NR3.

perhaps related?

http://www.economist.com/news/business/21648685-cloud-computing-prices-keep-falling-whole-it-business-will-change-cheap-convenient

Replaces Scoozzi’s

http://harvestwinebar.com/drink-menu.php

Hours of Operation: Mon – Fri 7:00am to 11:00pm
Sat – Sun 8:00am to 11:00pm
table cloth at nighthttp://www.santambroeus.com/sa_madison_avenue.html

http://www.economist.com/news/business/21648683-microchip-pioneers-prediction-has-bit-more-life-left-it-ever-more-moore

http://www.newyorker.com/magazine/2015/04/06/electrified

http://cancergenome.nih.gov/newsevents/newsannouncements/TCGA_The_Next_Stage

Make #precisionmedicine work for cancer http://www.nature.com/news/health-make-precision-medicine-work-for-cancer-care-1.17301 @MarkARubin1: >90% of…patients carry a mutation that may be drug-responsive

QT:{{"
“Hugely complicated genomic reports are rarely available in electronic form and are seldom tied to basic information about the patient. Whole-genome sequencing on tumour samples from nearly 14,000 people by the International Cancer Genome Consortium (ICGC), for instance, has revealed nearly 13 million mutations across the genome.

…
Since 2013, working with a team of computational biologists from Weill Cornell and the Centre for Integrative Biology at the University of Trento in Italy, my colleagues and I have conducted a pilot programme to determine the feasibility of tying genomic to clinical data in real time. So far, we have created easy-to-read reports for 250 people with cancer.
…
We have discovered that more than

"more than 90% of our patients carry a mutation that may be responsive to a known drug — although less than 10% of the patients may be eligible for a clinical trial either for logistical reasons or because there is insufficient evidence to warrant trying a non-approved drug.”
"}}